



Enzyme Inhibitor from Marine Organisms

Guest Editor:

Dr. Dirk Tischler

Tech Univ Bergakad Freiberg, Inst
Biosci, Environm Microbiol Grp,
Freiberg, Germany.
Ruhr-University Bochum,
Microbial Biotechnology Grp,
Bochum, Germany.

Deadline for manuscript
submissions:

closed (31 May 2020)

Message from the Guest Editor

Dear Colleagues,

Marine habitats are promising sources to identify novel organisms and compounds. A total of 70% of the planet's surface is covered by oceans, and little is known about the biosphere within these habitats. In the last few years, a number of original articles and reviews have reported on the potential of identifying novel bioactive compounds or secondary metabolites from marine environments. This is, and will be, a promising source for candidate compounds in pharma research and chemical biology. As in recent years, a number of novel techniques were introduced into the field and it has become easier to actually prospect for compounds, such as enzyme inhibitors. Those novel compounds than need to be characterized and evaluated in comparison to well-known representatives. This Special Issue focuses on the description of novel enzyme inhibitors of marine origin, including bioprospecting, omic approaches, structural and mechanistic aspects.

Dr. Dirk Tischler

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Bill J. Baker

Department of Chemistry,
University of South Florida, 4202
E. Fowler Ave., CHE 205, Tampa,
FL 33620-5250, USA

Message from the Editor-in-Chief

During the past few decades there has been an ever increasing number of novel compounds discovered in the marine environment. This is exemplified by the robust preclinical and clinical pipeline that currently exists for marine natural products. *Marine Drugs* is inviting contributions on new advances in marine biotechnology, pharmacology, chemical ecology, synthetic biology, and genomics approaches related to the discovery of therapeutically relevant marine natural products. Our goal is to share your contribution in a timely fashion and in a manner that will be valued by the scientific community.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [MEDLINE](#), [PMC](#), [Embase](#), [PubAg](#), [MarinLit](#), [AGRIS](#), and [other databases](#).

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmacology, Toxicology and Pharmaceutics (miscellaneous))

Contact Us

Marine Drugs Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/marinedrugs
marinedrugs@mdpi.com
X@Marine_Drugs